Search Videos and More

Showing 1 - 12 of 22 results

Previous| 1 | 2 |Next


Dana-Farber Research Supports FDA Approval of Immunotherapy Drug Given After Surgery for Certain Patients with Kidney Cancer News

Dana-Farber Research Supports FDA Approval of Immunotherapy Drug Given After Surgery for Certain Patients with Kidney Cancer

Pembrolizumab is the first drug approved as adjuvant therapy for patients with kidney cancer considered at high risk of relapse.
Rare Cancer: A Father's Journey with Medullary Kidney Cancer Video

Rare Cancer: A Father's Journey with Medullary Kidney Cancer

A father and Air Force recruiter details his journey at Dana-Farber Cancer Institute with medullary kidney cancer - a rare cancer disproportionately affecting African Americans.
Newsweek Names Dana-Farber #3 in the World for Cancer News

Newsweek Names Dana-Farber #3 in the World for Cancer

Dana-Farber Cancer Institute has been named one of the world’s very best cancer hospitals by Newsweek in its new World’s Best Specialized Hospitals 2022 rankings.
Kidney Cancer Research at ESMO Video

Kidney Cancer Research at ESMO

Dana-Farber's Toni Choueiri, MD, provides insight on KEYNOTE-564 trial in kidney cancer highlighted at ESMO 2021.
Bladder Cancer Research at ESMO Video

Bladder Cancer Research at ESMO

Dana-Farber's Guru Sonpavde, MD, provides insight on circulating tumor DNA trial in bladder cancer highlighted at ESMO 2021.
Study Pairs Two Forms of Immunotherapy in Patients with Advanced Kidney Cancer News

Study Pairs Two Forms of Immunotherapy in Patients with Advanced Kidney Cancer

T cells revved up to attack tumors are turned into an army of loiterers. Cells keenly attuned to signals of infection or disease fail to pick up the faint notes of cancer. A clinical trial led by Dana-Farber researchers is addressing both of these issues in patients who have undergone surgery for kidney cancer but have a high risk of recurrence.
Study Finds Lower Mortality Rate for Men at High Risk for Death from Prostate Cancer Who Received Early Postoperative Radiation Therapy News

Study Finds Lower Mortality Rate for Men at High Risk for Death from Prostate Cancer Who Received Early Postoperative Radiation Therapy

In a large, international retrospective study, men at high risk for death from prostate cancer had a significant reduction in all-cause mortality if treated with radiation shortly after surgery
Immunotherapy Drug Delays Recurrence in Kidney Cancer Patients News

Immunotherapy Drug Delays Recurrence in Kidney Cancer Patients

Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.
Bladder Cancer Advances Video

Bladder Cancer Advances

Dana-Farber's Guru Sonpavde, MD discusses two studies with promising results. One study looks at pre-operative therapy, the other study compares an antibody-drug conjugate to chemotherapy in urothelial carcinoma.
Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research Video

Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research

In our exclusive interview, Dr. Choueiri and Dr. Motzer discuss the clinical implications of the phase 3 CheckMate-9ER trial in advanced renal cell carcinoma and how to best use the combination in practice.
New Treatments for Bladder Cancer Patients Video

New Treatments for Bladder Cancer Patients

Bladder cancer therapies, once very limited, now offer more options to treat patients than ever before. Dana-Farber Cancer Institute's Bladder Cancer Director, Guru Sonpavde, MD, details new treatments and research initiatives on the horizon for bladder cancer.
Dana-Farber Research Leads to Better Understanding of the Immune System in Kidney Cancer News

Dana-Farber Research Leads to Better Understanding of the Immune System in Kidney Cancer

In the last two decades, immunotherapy has emerged as a leading treatment for advanced renal carcinoma cancer (more commonly known as kidney cancer). This therapy is now part of the standard of care, but it doesn’t work for all patients, and almost all patients, no matter how they respond initially, become more resistant to treatment over time.

Showing 1 - 12 of 22 results

Previous| 1 | 2 |Next